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Abstract 32 
Purpose: The brain can utilise medium chain triglycerides (MCTs) as an alternative fuel than 33 
glucose, and research has shown that MCT ingestion improves cognitive function in diseased 34 
and/or elderly individuals. The aim of this study is to determine if these improvements can also 35 
be observed in young, healthy adults. Furthermore, we aim to establish the ideal dosage and 36 
timeframe necessary for an effect. 37 
 38 
Methods: Participants were divided equally into three groups of 10 (Placebo (0g), 12g and 18g 39 
MCT/day) and were supplemented for 4 weeks. The supplement had a C8:C10 ratio of 30:70. 40 
Participants visited the laboratory once a week for 5 weeks (baseline, test weeks 1-4) to undergo 41 
a battery of cognitive tests; Trail Making, Digit Span, Spatial Span, Covert Shift of Attention, 42 
and Rapid Visual Information Processing. 43 
   44 
Results: After 2-3 weeks of supplementation, MCT ingestion enhanced performance in 45 
cognitive tasks, including: Trail Making A/B and Digit Span Forwards/Backwards (ps<0.001) 46 
when compared to a placebo group taking a carbohydrate gel. In Spatial Span Backwards, there 47 
was a significant main effect of group (p=0.002). Where significance was seen, there were 48 
main effects of time after 2-3 weeks (ps<0.05). There was minimal difference between the two 49 
MCT intervention groups in most measures (ps>0.05). There were also null results in tasks 50 
measuring attention and reaction time (ps>0.05).  51 
  52 
Conclusions: MCT ingestion improved cognitive performance after 2-3 weeks, with minimal 53 
difference between taking 12g and 18g MCT/day groups, suggesting a possible dose-response 54 
threshold at 12g MCT/day when supplementing over a short period. 55 
 56 
Keywords: MCTs, Processing Speed, Task Switching, Working Memory, Cognition57 
Introduction 58 
Medium chain triglycerides (MCTs) are mixed fatty acids with a chain length of between 6 and 59 
12 carbon atoms. Naturally occurring sources of MCTs include coconut oil, palm kernel oil 60 
and breast milk. For the most part, commercially produced MCTs contain two predominant 61 
fatty acids in varying ratios; Caprylic Acid (C8) and Capric Acid (C10), with only traces of C6 62 
and C12 [1,2]. MCTs are less common in Western diets, with the majority of the fatty acids 63 
consumed being long-chain fatty acids (LCFAs), i.e. containing more than 12 carbon atoms 64 
[3]. These LCFAs are provided by animals/vegetable oils and fat sources which are vital for 65 
essential bodily functions [4]. Despite not normally being present in typical western diets, 66 
MCTs are increasingly being incorporated into a growing number of food and nutrition plans 67 
due to their potential health benefits [1]. 68 
 69 
Digestion of MCTs begins in the mouth by the enzyme lingual lipase which is present 70 
in saliva. Figure 1 highlights that they are then hydrolysed in the stomach and intestine by 71 
pancreatic lipase into medium chain fatty acids (MCFAs) and monoglycerides. This is a faster 72 
and more complete process than that of long chain triglycerides (LCTs) [1,5], with MCFAs 73 
being absorbed directly into the portal vein, bound to albumin, just minutes after ingestion [3]. 74 
Moreover, absorption of MCTs may not require bile and lipase, and therefore, are directly 75 
absorbed by the enterocytes [6]. Thus, they are unlike LCFAs, which are firstly incorporated 76 
into chylomicrons before being transported into the lymphatic system and taken to the liver [7–77 
9]. The liver oxidises the majority of the MCFAs via β-oxidation [10], leading to the production 78 
of ketones, predominantly β-hydroxybutyrate (βHB) [1], as shown in Figure 1. The formation 79 
of βHB, as well as acetoacetate and acetone, is normally the result of a greater availability and 80 
oxidation of fatty acids in the liver due to an extended low carbohydrate intake, or during 81 
prolonged exercise. However, MCTs enable the body to produce these compounds without a 82 
change in diet. The acetone formed, arguably, may be used as a gluconeogenic substrate, 83 
although it is mainly excreted through urine or exhaled as a waste product. The feasibility of 84 
glucose being produced from fatty acids is a very controversial mechanism. It was initially 85 
thought that acetone can contribute carbon atoms to glucose formed by the Krebs Cycle [11], 86 
however, in the 1980’s, new pathways were discovered [12–14]. Recently, Kaleta et al. [15] 87 
identified 58 possible pathways acetone can take to become glucose. This relatively recent 88 
finding contradicts previous assumptions that humans are unable to metabolise acetone, and 89 
therefore fatty acids, into glucose. In contrast to LCFAs, MCFAs can transport through the 90 
mitochondrial membrane regardless of the presence of carnitine [16,17], allowing oxidation to 91 
proceed more rapidly than that of LCFAs [9]. Taken together, the ingestion of MCTs is more 92 
ketogenic (i.e. produces ketones more rapidly) in comparison to LCTs, [7,18]. For a thorough 93 
comparison of MCTs and LCTs, see Jeukendrup and Aldred [3]. 94 
 95 
βHB is exported from the liver into the blood and is converted in the mitochondria in 96 
muscle and brain cells into acetoacetate using the enzyme beta-hydroxybutyrate 97 
dehydrogenase. Acetoacetate is then converted to acetoacetyl-CoA via the enzyme succinyl-98 
CoA-oxoacid CoA transferase before becoming acetyl-CoA via the enzyme beta-ketoacyl-99 
CoA, which is then oxidised in the Krebs cycle with the subsequent NADH and FADH2 100 
production utilised by the mitochondrial electron transport chain to harbour energy [19,20], as 101 
illustrated in Figure 1. The brain can utilise βHB as an alternate energy source to glucose, which 102 
is otherwise the main fuel source [10,21]. Additionally, the MCFAs that bypass metabolism in 103 
the liver can directly cross the blood-brain-barrier due to their relatively shorter carbon chain 104 
length and are oxidised in astrocytes: LCFAs are unable to do so [22,23]. Therefore, MCTs 105 
provide both direct and indirect (via βHB) additional fuel sources for the brain [21]. 106 
 107 
[Insert Figure 1 Around Here] 108 
 109 
Since MCTs provide several routes of energy supply for brain metabolism [21], and in 110 
light of the potential for cerebral insulin resistance in elderly/diseased individuals [24–26], it 111 
has been suggested that ingestion of MCT supplements alongside a regular diet can offset 112 
cognitive decline in these populations [21,25–29]. For example, Page et al. [29] found that, in 113 
diabetic individuals, acute MCT ingestion increased performance in digit symbol coding and 114 
total map searching, while preventing declines in tests requiring verbal working memory and 115 
attention when experiencing hypoglycaemia. Memory performance was also improved in 116 
participants with Alzheimer’s disease [25–28] and mild cognitive impairment [30] following 117 
both acute and chronic MCT loading protocols. In healthy elderly participants, Ota et al. [21] 118 
demonstrated cognitive improvements in digit span and trail making tasks following a single 119 
20g serving of MCTs, although no such effects were indicated by O’Neill et al. [31] after 14 120 
successive days of MCT ingestion, possibly due to the very high rates of diarrhoea experienced 121 
by participants impacting on treatment efficacy.  122 
 123 
Diseased and/or elderly individuals are more likely to have a reduced baseline cognitive 124 
function, possibly due to cerebral insulin resistance, such that it has been proven that ketogenic 125 
interventions lead to βHB becoming a primary energy source for the brain, alleviating cognitive 126 
dysfunction [24–26]. However, even in young healthy individuals, the range of substrates 127 
available to the brain for energy metabolism remains restricted as compared to skeletal muscle, 128 
for example. Specifically, the brain relies on glucose, ketones and MCTs for energy, whilst 129 
being unable to utilise LCTs. Moreover, there are no significant differences in brain ketone 130 
metabolism between older adults, individuals with cognitive impairment/Alzheimer’s Disease 131 
and healthy young adults [32–34]. Therefore, it remains plausible that the improvements in 132 
cognitive function following MCT supplementation demonstrated in diseased/elderly 133 
populations may also be seen in healthy subjects. 134 
 135 
Typically, commercially available MCT products contain varying ratios of C8 and C10 136 
[2]. C8 has been shown to be more ketogenic than C10 [7,18], and preferentially metabolised by 137 
neuronal cells, whereas C10 is metabolised at a slower rate, leading it to accumulate [35]. 138 
However, C10 is easier to digest than C8 due to its longer carbon chain length, reducing the risk 139 
of gastronomical distress [1,36]. Hence, adherence to MCT supplementation may be impacted 140 
by the C8-C10 ratio. Vandenberghe et al. [18] demonstrated that only a modest amount of C8 is 141 
required (within a C8-C10 mixture) to retain a peak plasma ketone response no different to that 142 
of C8 alone. Moreover, C10, rather than C8, has the potential to increase the number of 143 
mitochondria over time in neuronal cells, although of a smaller size than untreated cells [37].  144 
Hughes et al. [37] observed that C10, but not C8, increased citrate synthase activity after 6 days 145 
of MCT supplementation, indicative of enhanced mitochondrial biogenesis. This effect may be 146 
due, at least in part, to the peroxisome proliferator activator receptor γ (PPARγ), a promotor of 147 
mitochondrial biogenesis [38], which is activated by C10, but not C8. [39]. Hughes et al. found 148 
that in the presence of a PPARγ antagonist, the increase in citrate synthase activity due to C10 149 
was prevented. Taken together, these data are supportive of the notion of mitochondrial 150 
biogenesis being induced in neuronal cells following C10 MCT supplementation. 151 
 152 
The present study utilised a C8-C10 ratio of 30:70 in the MCT supplement. This 153 
incorporates the benefits of both C8 and C10, while also limiting the risk of gastronomical 154 
distress previously seen when using a supplement with a higher ratio of C8 [27,40]. The primary 155 
aim was of this study is to determine whether the improvements in cognitive function due to 156 
MCT ingestion seen in diseased/elderly individuals will also be demonstrated in a young and 157 
healthy population. We hypothesised that chronic MCT ingestion would improve some aspects 158 
of cognitive function, as measured by a standardised battery of laboratory-based cognitive tests 159 
including trial making, digit and working memory span, covert shift of attention, and rapid 160 
visual information processing (sustained attention). Following previous findings that used 161 
similar measures [21,25–30], we predicted there to be improvements within at least some of 162 
the tasks, most likely in the trail making and memory span tasks, as demonstrated by Ota et al. 163 
[21,26]. This study has the secondary aim of establishing the minimum effective dose of this 164 
unique MCT composition during a 4-week period of supplementation. 165 




30 university students (19.7 ± 1.5 years, 16 males and 14 females) volunteered for the present 170 
study. Participants were all clear of any neurological and health impairments and had not 171 
partaken in any cognitively demanding tasks for at least 12 hours prior to each testing session. 172 
The study was approved by the local research ethics committee (approval number: S 22-11-19 173 
PA 053) and designed and conducted in accordance with the Declaration of Helsinki (2013). 174 
 175 
 176 
Experimental Procedure 177 
The study followed a repeated-measures, single-blind design involving a single weekly visit to 178 
the laboratory at the exact same time for 5 consecutive weeks. After a 12h overnight fast, 179 
participants undertook a single battery of cognitive tests at each visit, which lasted < 30 mins. 180 
Baseline measurements were taken before the participants had started their supplementation 181 
period due to the fact that it takes a number of days before C10 has a significant effect upon 182 
mitochondrial function [37], and up to 72h for ketones to be metabolised in the brain of 183 
nondiabetic individuals [41]. Each successive round of testing took place after 7 successive 184 
days of supplementation, with the participants taking an MCT/placebo gel immediately prior 185 
to their laboratory visits. Participants took the gels every day for a total of 4 weeks to ensure 186 
sufficient time for an increase in blood plasma ketone bodies (acetoacetate and β-187 
hydroxybutyrate) [28]. 188 
 189 
Participants were randomly allocated into one of 3 groups using a random number 190 
generator using computer software, and the groups were matched for age and gender: Placebo 191 
(0g MCT/day), 12g MCT/day and 18g MCT/day. The MCT was provided to participants using 192 
a commercially available MCT gel (Nuroco, London, UK) that contains 59 kcal and 6g of MCT 193 
with a 30:70 ratio of C8:C10. In order to offset possible unpleasant gastronomical issues that 194 
arise from taking MCTs [40], the number of MCT gels (6g) given to the 12g and 18g groups 195 
were increased incrementally over the course of the 4-week period (Figure 2). To match the 196 
number of overall gels taken by all participants, a carbohydrate gel (Energel+, Nutrition X, 197 
Gloucester, UK) was provided with similar calorific intake (94 kcal, difference 35 kcal vs. 198 
MCT gel) and flavouring to that of the MCT gel. All gels were wrapped in black tape to blind 199 
them from the participants. Participants were instructed to take their first, second and third gels 200 
30 mins prior to breakfast, lunch and dinner, respectively. When visiting the lab, participants 201 
were instructed to take their gel immediately prior to entering the laboratory to and have 202 
breakfast as soon as possible after completion of the tests in order to abide by the instructed 203 
30-minute interval between gels and meals as closely as possible. 204 
 205 
[Insert Figure 2 Around Here]  206 
 207 
Cognitive Assessments 208 
 209 
Trail Making 210 
Trail Making (TM) broadly assesses processing speed, sequencing and visual-motor skills [42]. 211 
There are two parts; A and B. In part A, participants are required to draw lines as quickly as 212 
possible between the numbers 1 and 25 in ascending order. In part B, participants are required 213 
to draw lines as quickly as possible between the ascending orders of both numbers (1-13) and 214 
letters (A-L). Due to the need to switch attention between letters and numbers in part B (1-A, 215 
2-B, etc.), it is comparably much more difficult than part A. If any errors were made, it was 216 
immediately pointed out by the experimenter and the participant had to correct for it. 217 
Participants initially practiced for each part, which comprised of only 8 circles. 218 
 219 
Memory Span 220 
Two aspects of working memory were assessed: verbal and visuo-spatial. Verbal working 221 
memory was assessed using the digit span test (DS) and visuo-spatial working memory was 222 
assessed using the spatial span test (SS). The experimenter either read out a series of numbers 223 
(DS) or tapped blocks in a certain predetermined order (SS). The participants had to either 224 
repeat the numbers back (DS) or tap the blocks (SS) in the corresponding order (forwards test 225 
phase) or in reverse order (backwards test phase). The backwards test phase is comparably 226 
more difficult than the forwards test phase due to the requirement of the executive function to 227 
re-order items before responding [43]. There were two trials in each item, with the number of 228 
numbers/blocks increasing by one item every trial. The test was terminated when participants 229 
incorrectly recalled a sequence on both trials of any one item or recalled all items correctly. 230 
Each test phase had a maximum score of 16, with the exception being DS backwards, which 231 
had a maximum score of 14. There was no practise necessary due to the first trials only being 232 
2 numbers/blocks long, which was sufficiently easy to gain a full understanding of the task. 233 
 234 
Covert Shift of Attention (CSoA) 235 
Exogenous (involuntary) and endogenous (voluntary) attention were assessed via a covert 236 
attention paradigm [44]. Each test involved rapidly responding to a cue that was presented on 237 
an LCD monitor using Matlab (MathWorks, Natick, MA, USA) running Psychtoolbox (version 238 
3.0.11). Stimuli featured a background with a white crosshair at screen-centre, and two unfilled 239 
white squares at a 5-degree horizontal eccentricity. Participants were instructed to fixate on the 240 
crosshair while they used their left or right index fingers to press the ‘f’ or ‘j’ keys on a 241 
keyboard in response to the left or right white squares becoming filled, respectively. 242 
 243 
The exogenous and endogenous tests were differentiated by the unique characteristics 244 
of a pre-cue. For exogenous cuing, the pre-cue initially involved a white unfilled square 245 
surrounding one of the other two squares for 50ms. Therein, one of the two squares became 246 
filled for 1500ms or until the participants responded. Trials could be discriminated by the 247 
relation between the side of space of the initial pre-cue and the location of the response cue. 248 
That is, a compatible relation between the side of space of the pre-cue and location of the 249 
response cue was regarded as a cued trial, while an incompatible relation was regarded as an 250 
uncued trial. The time difference between the pre-cue and response cue was set to 100ms and 251 
800ms in order to exercise processes of cue facilitation and inhibition, respectively. That is, a 252 
100ms asynchrony typically generates a quicker response for cued compared to uncued trials 253 
(facilitation), while a 800ms asynchrony typically generates the inverse effect (inhibition) 254 
[45,46]. There was an equal distribution of 20 trials for each type of trial (cued, uncued), side 255 
of space (left, right) and stimulus-onset asynchrony (100ms, 800ms). In addition, there were 256 
16 catch trials where a response cue would not appear following the initial pre-cue, and thus 257 
required no response. Thus, there were total of 96 trials for the experiment and 20 trials for 258 
initial practice. 259 
 260 
For endogenous cuing, the pre-cue initially involved a set of white arrowheads (<< / 261 
>>) appearing at screen-centre for 50ms. Following a further delay of 450ms, one of the two 262 
squares was filled in white for 1500ms or until the participants responded. In a similar vein to 263 
exogenous cuing, trials could be discriminated by the nature of the initial pre-cue and the 264 
location of the response cue. That is, a compatible relation between the direction of pre-cue 265 
and location of the response cue was regarded as a valid trial, while an incompatible relation 266 
was regarded as an invalid trial. Importantly, the frequency of valid trials was noticeably greater 267 
than invalid trials, which typically cues attention toward the same direction as the pre-cue. 268 
Consequently, the ability to inhibit and reorient attention can be found when reducing the extent 269 
of the typically quicker responses for valid compared invalid trials [45,46]. There were 32 270 
valid, 8 invalid and 8 catch trials–comprising a total of 48 trials–for the experiment and 10 271 
trials for initial practice. 272 
 273 
Reaction times were recorded as the time difference between stimulus and response 274 
onset. Trials where there was a false (<100ms) or delayed (>1000ms) reaction, or responses 275 
were made to the incorrect side of space were removed from any subsequent calculations. The 276 
dependent measure involved the cuing effect, which was calculated as the mean participant 277 
reaction time to the cued/valid trials minus the uncued/invalid trials. Thus, a more negative 278 
score indicated a quicker response to the cued/valid trials than the uncued/invalid trials. 279 
 280 
Rapid Visual Information Processing (RVIP) 281 
RVIP assesses the ability to sustain attention to visual stimuli [47–49]. Stimuli featured single 282 
digits (1-10) being sequentially presented at the centre of an LCD monitor. Participants were 283 
instructed to press the spacebar key of a keyboard as soon as a digit was presented that 284 
completed a unique three-digit sequence: 2-4-6, 4-6-8, 3-5-7. Each digit was presented for 285 
600ms with no inter-stimulus interval. However, the digits were alternatively presented for 286 
1500ms whenever they completed a target sequence. There were 8 target sequences per min, 287 
and the test lasted continuously for 5mins (100 digits per min). Prior practice on the test was 288 
completed over 1min. The dependent measures involved reaction times to target sequences, 289 
proportion of false (<100ms) or delayed (>1000ms) reactions, and proportion of missed targets. 290 
 291 
Statistical Analysis 292 
The data were analysed through linear mixed modelling (LMM) using the statistical package 293 
IBM SPSS Statistics (Version 25, Chicago, IL, USA). An LMM was utilised due to its ability 294 
to provide unbiased data in the presence of missing data (there was 57 missing data points from 295 
a total of 1800) [50]. Baseline measurements were entered as a covariate and the treatment 296 
effect from baseline (i.e. difference from baseline) were analysed in each measure. All models 297 
began as a null and were progressed to more complex parsimonious hierarchical models. The 298 
4 time points (weeks 1, 2, 3 and 4) and the three experimental groups (Placebo, 12g and 18g) 299 
were treated as categorical fixed effects. Random effects were associated with the individual 300 
participants. Significant effects were decomposed using the Fisher LSD post hoc procedure. 301 
 302 
A basic variance components model was executed to calculate the intraclass correlation 303 
(ICC) of the random factors for participant number to determine if any contributed significance 304 
variance to the dependent variable, as seen in Table 1. Model fit was assessed using Akaike’s 305 
information criterion (AIC). For the dependent variable (treatment effect), AIC revealed the 306 
models that best fit the data utilised either the AR-1 or AR-1: Heterogenous repeated 307 
covariance structure for the repeated measures. Significance was set at P<.05. Where 308 
appropriate, post hoc analyses (LSD) and the inclusion of 95% confidence intervals (CI) of the 309 





Variance Calculations 315 
Table 1 shows the ICC’s (%) of the random factors accounted for in the linear model. The 316 
individuals contributed significant variance to the dependent variable in all measures. Hence, 317 
they were included in all of the larger hierarchical models. 318 
[Insert Table 1 Around Here] 319 
Trail Making 320 
For TM A, there was no significant main effect of group (p=0.149), although there was a 321 
significant main effect of time (p<0.001). This effect was superseded by a significant group x 322 
time interaction (p<0.001) (Figure 3A). Post hoc analysis revealed that the 12g group 323 
performed significantly better than the Placebo group in week 4 (p=0.045). The 18g group 324 
performed significantly better than the Placebo group in weeks 3 (p=0.001) and 4 (p<0.001), 325 
and the 12g group in weeks 3 (p=0.014) and 4 (p=0.001). There were no further significant 326 
differences in any of the weeks (ps > .05). 327 
For TM B, there was no significant main effect of group (p=0.065), although there was 328 
a significant main effect of time (p<0.001). This effect was superseded by a significant group 329 
x time interaction (p<0.001) (Figure 3B). Post hoc analysis revealed that the 12g and 18g 330 
groups performed significantly better than the Placebo group in weeks 2 (p=0.018; p=0.023), 331 
3 (p=0.018; p=0.001) and 4 (p=0.016; p=0.001), respectively. There was no significant 332 
difference between the 12g and 18g groups in any of the weeks (ps > .05).  333 
Memory Span 334 
For DS Forwards, there were significant main effects of both group and time (ps<0.001). These 335 
effects were superseded by a significant group x time interaction (p<0.001) (Figure 3C). Post 336 
hoc analysis revealed that the 12g and 18g groups significantly outperformed the Placebo group 337 
in weeks 2 (p<0.001; p=0.007), 3 (ps<0.001) and 4 (ps<0.001), respectively. There was no 338 
significant difference between the 12g and 18g groups in any of the weeks (ps > .05). 339 
For DS Backwards, there were significant main effects of both group (p=0.001) and 340 
time (p<0.001). These effects were superseded by a significant group x time interaction 341 
(p<0.001) (Figure 3D). Post hoc analysis revealed that the 12g and 18g groups significantly 342 
outperformed the Placebo group in Weeks 2 (p=0.009; p<0.001), 3 (ps=0.002; p<0.001) and 4 343 
(ps<0.001), respectively. There was no significant difference between the 12g and 18g groups 344 
in any of the weeks (ps > .05). 345 
In SS Forwards, there were no significant main effects of group (p=0.591) and time 346 
(p=0.883), nor a significant group x time interaction (p=0.435) (Figure 3E).  In SS Backwards, 347 
there was a significant main effect of group (p=0.002), which indicated that the Placebo group 348 
was outperformed overall by the 12g (mean=1.3 ± .38; 95% CI=52 to 2.1) and 18g (mean=1.3 349 
± .38; 95% CI=.50 to 2.1) groups, although, there was no significant difference between the 350 
12g and 18g groups. There was also a significant main effect of time (p=0.001), which indicated 351 
that when compared to week 1, performance was significantly better in weeks 2 (mean=0.77 ± 352 
.19; 95% CI=.40 to 1.1), 3 (mean=0.77 ± .23; 95% CI=.31 to 1.2), and 4 (mean=0.77 ± .25; 353 
95% CI=.25 to 1.3) (Figure 3F). However, there was no significant group x time interaction 354 
(p=0.801). 355 
[Insert Figure 3 Around Here] 356 
Covert Shift of Attention (CSoA) 357 
For the exogenous test, there were 1122 out of 14400 trials (7.79%) that were in error, and thus 358 
removed prior to analysis. In the endogenous test, 469 out of 7200 trials (6.51%) were removed 359 
prior to analysis due to being in error. 360 
In the exogenous test, there appeared to be general cue facilitation and inhibition effects 361 
courtesy of the negative (cued < uncued) and positive (cued > uncued) scores for the 100ms 362 
and 800ms asynchronies, respectively (Table 2). For the 100ms asynchrony, there were no 363 
significant main effects of group (p=0.672) and time (p=0.461), nor a significant group x time 364 
interaction (p=0.665). Likewise, for the 800-ms asynchrony, there were no significant main 365 
effects of group (p=0.201) and time (p=0.111), nor a significant group x time interaction 366 
(p=0.873). 367 
For the endogenous test, there appeared a general cuing effect courtesy of the negative 368 
scores (valid < invalid) (Table 2). However, there were no significant main effects of group 369 
(p=0.91) and time (p=0.619), nor a significant group x time interaction (p=0.222). 370 
[Insert Table 2 Around Here] 371 
Rapid Visual Information Processing (RVIP) 372 
For RT, there were no significant main effects of group (p=0.407) and time (p=0.858), nor a 373 
significant group x time interaction (p=0.132) (Table 3). Likewise, for errors due to responding 374 
to a non-target, there were no significant main effects of group (p=0.529) and time (p=0.251), 375 
nor a significant group x time interaction (p=0.134). 376 
For errors due to missing targets, there was no significant main effect of group 377 
(p=0.753), although there was a significant main effect of time (p<0.001) (Table 3). Post hoc 378 
analysis revealed that compared to week 1, there were less errors in weeks 3 (mean=-9.9 ± 2.1; 379 
95% CI = -14.1 to -5.8) and 4 (mean=-9.1 ± 2.1; 95% CI = -13.4 to -4.8). Furthermore, when 380 
compared to week 2, less errors in weeks 3 (mean=-6.6 ± 1.9; 95% CI = -10.4 to -2.9) and 4 381 
(mean=-5.8 ± 2.1; 95% CI = -10.0 to -1.6). There was no significant difference between weeks 382 
1 and 2 (p=0.073), nor between Weeks 3 and 4 (p=0.671). Meanwhile, there was no significant 383 
group x time interaction (p=0.197). 384 
[Insert Table 3 Around Here] 385 
Participant Feedback  386 
After week 4 of supplementation, the participants filled out a feedback form. The most pressing 387 
issues were those of side effects. If introduced too quickly, MCTs are known to potentially 388 
cause gastrointestinal issues [1,36] due to their relatively short carbon chain. In order to reduce 389 
this risk, the MCTs dosages used were relatively low. Our study used a maximum total dose of 390 
18g of MCT/day. This amount was also used by Xu et al. [28], and their participants 391 
experienced little to no side effects. Furthermore, the dosage was gradually increased week by 392 
week and the supplement contained a higher ratio of C10, which causes fewer stomach issues 393 
than C8. Despite this, some minor side effects were experienced by 50% of the 18g group and 394 
by 40% of the 12g group. 395 
Discussion 396 
The present study aimed to determine if chronic MCT ingestion improved performance in 397 
cognitive tasks for healthy individuals, and if so, quantify the ideal dose and time frame to elicit 398 
these improvements. Our data suggests that MCT supplementation improves cognitive 399 
performance in healthy individuals after a minimum of 2-3 weeks, following ingestion of 12 -400 
18g of MCTs per day. This dose was similar to the 17.3g MCT/day used by Xu et al. [28], who 401 
demonstrated improvements in cognition after 30 days of supplementation. As the participants 402 
in the present study supplemented MCTs alongside their habitual diet, the findings suggest that 403 
MCT ingestion improves cognition independent of overall macronutrient composition [19,51]. 404 
Hence, MCT supplementation can be incorporated much more easily into people’s diets rather 405 
than needing to have a fully ketogenic diet. 406 
The increased cognitive performance by the 12g and 18g groups in both test phases of 407 
TM compared to the placebo group provides a firm basis for accepting the hypothesis that 408 
MCTs would increase cognitive performance in this regard; specifically processing speed, 409 
sequencing and/or visual-motor skills. In the A test phase, the 18g group’s performance 410 
increased after three weeks whereas it took four weeks for the 12g group to outperform the 411 
placebo group. However, the 18g group still outperformed the 12g group in week 4. In the B 412 
test phase of the TM task, both the experimental groups performed significantly better than the 413 
placebo group in weeks 2, 3 and 4. This suggests that the higher MCT dose accelerated and 414 
increased the improvement in performance in A, whereas dosage did not matter in B. The fact 415 
that the MCTs improved performance in this task follows on from Ota et al. [21], where they 416 
saw a similar improvement in TM following their administration of MCT within healthy elderly 417 
patients. However, the present study featured healthy, young participants with naturally 418 
comparatively higher cognitive function at baseline, meaning these results are perhaps easier 419 
to generalise to the wider population. It is of interest for future investigations to perhaps 420 
decompose this influence of MCT on TM, including the separate contributions of cognitive and 421 
visual-motor components. 422 
There were positive findings regarding the working memory tests, supporting previous 423 
findings that MCTs can improve performance in memory tests [21,25–28]. In weeks 2-4, the 424 
experimental groups performed significantly better than the placebo group in digit working 425 
memory tasks with no difference between the two groups. However, in the SS task, the 426 
forwards test phase showed no significant difference between the groups at any time point, 427 
whereas the 12g and 18g group outperformed the placebo group overall in the backwards test 428 
phase. This is possibly because the backwards test phase is more demanding than the forwards 429 
phase, meaning there is greater scope for improvement. These results support Ota et al. [21], 430 
showing that the effects of the MCTs were more abundant in DS performance than for SS. The 431 
present study therefore builds on previous data that MCTs can improve different aspects of 432 
memory span, both in cognitively impaired and healthy populations. 433 
The CSoA measure indicated that there were no differences between the MCT and 434 
Placebo groups throughout the study weeks. Specifically, there was no change within the 435 
exogenous cuing task, where responses are usually quicker at a short asynchrony (100ms) 436 
(facilitation), but inversely slower at a long asynchrony (800ms) (inhibition), following the 437 
presentation of cued compared uncued stimuli [44]. Likewise, there was no change within the 438 
endogenous cuing task, where responses are usually biased toward the same side of space as a 439 
disproportionately presented pre-cue. These cuing tasks have been known to be heavily 440 
influenced by related factors such as vestibular inputs [52], testosterone levels [53], and age 441 
[54]. Moreover, the visual selective attention processes that are associated with these cuing 442 
tasks can be attributed to a broad neural network that comprises the parietal, frontal and 443 
premotor cortices [55]. While it is premature at best to suggest that these neural regions remain 444 
unaffected by MCTs-especially considering the previously stated influences on TM and 445 
memory span both in the present study and in previous work [21,25–28]–it is possible that any 446 
influence of MCTs within cognitive performance does not extend specifically to visual 447 
selective attention. 448 
In the RVIP task, MCTs did not influence RT and the amount of responses to non-449 
targets, in spite of previous evidence indicating that different types of fatty acids (e.g., Omega-450 
3 polyunsaturated [56]) can improve sustained attention. There was, however, an overall 451 
continual decrease in the amount of errors from not responding to the targets that was 452 
independent of any the groups. The fact that there was no difference between the groups in this 453 
regard suggests that this improvement was due to a mere learning effect. It may be that the 454 
RVIP task for sustained attention is not sensitive enough to detect small changes between trials 455 
due to the relatively small doses of MCTs used in this study [49]. Future investigations should 456 
adapt the task to overcome this. One suggestion is to increase the task time [57] and/or increase 457 
the number of stimuli in order to increase mental fatigue.  However, from the evidence that is 458 
currently available, it would suggest that the influence of MCTs on cognitive performance also 459 
does not comprise of the ability to sustain attention. 460 
MCTs have repeatedly been shown to benefit cognitive performance in diseased and 461 
healthy populations [21,25–29]. The present study has shown this intervention to be similarly 462 
beneficial in some regards in healthy, young individuals. The mechanisms underpinning this 463 
effect is considered to be via an augmentation of energy supply to the brain in the form of βHB 464 
and MCFA, both of which are rapidly available to the brain in excess following ingestion of 465 
MCTs [21]. However, due to the relatively low doses of MCTs used in the present study, the 466 
increases in cognitive performance are likely due to an increased rate of mitochondrial 467 
biogenesis. This is possibly due to the increased activation of PPARγ, owing to the high 468 
proportion of C10 ingested by the participants [37]. Nevertheless, the majority of studies, 469 
including the present data, show that the benefits to cognitive function are only revealed after 470 
either a number of weeks of daily supplementation, or a very high acute dose, the latter of 471 
which increases the risk of side effects [21,25–29]. The former may be an artefact of improved 472 
tolerance to MCT ingestion with time, resulting in improved absorption and thus entry into the 473 
circulation. In the present study, MCT ingestion was increased on a weekly basis in each group 474 
as a means to avoid acute intolerance of the supplementation regimen; hence the improvements 475 
to cognitive function may be as a result of reaching some critical threshold of acute MCT 476 
consumption. 477 
An alternative mechanism whereby chronic MCT ingestion enhances cognitive 478 
performance is via metabolic adaptations within the participant’s brain cells; namely increasing 479 
mitochondria number; improving mitochondrial function and reducing mitochondrial oxidative 480 
damage [27,37]. C10 (which was favoured in the present study), but not C8, has been shown to 481 
result in increased citrate synthase and complex I activity in isolated neuronal cells [37], with 482 
concomitant evidence of mitochondrial biogenesis. The fact it took several weeks for the effects 483 
on cognitive performance to display, suggests that the positive results herein were due to one 484 
or more of the chronic adaptations outlined above. 485 
Irrespective of the specific mechanisms underpinning the augmentation of cognitive 486 
performance, most previous studies have favoured C8 in the supplementation regimen 487 
[21,25,27] since this has been shown to be more ketogenic than C10 [18]. However, 488 
gastrointestinal distress  is more common and severe with C8 as compared to C10 [36], thus 489 
impacting on participant compliance. Therefore, we utilised a 30:70 ratio of C8:C10 in the 490 
present study to off-set these issues. Whilst the data of Vandenberghe et al. [18] suggest this 491 
may have blunted the ketogenic response to each gel, their data also demonstrates that only a 492 
modest amount of C8 is required (within a C8-C10 mixture) to retain a peak plasma ketone 493 
response no different to that of C8 alone. Moreover, the single-day design of [18] does not 494 
replicate the chronic ingestion regimen adopted in the present study. 495 
Whilst we were unable to undertake blood sampling to determine plasma ketone 496 
concentrations in the present study, it seems possible that the chronic nature of the MCT 497 
ingestion regimen and the mixture of C8-C10 utilised resulted in augmentation of ketone and 498 
MCFA supply for the purposes of brain metabolism. This, alongside the metabolic adaptations 499 
C10 elicits, explains the positive effects seen in the cognitive task performances. Specifically, 500 
there were improvements in Trail Making A and B, Digit Span forwards and backwards, and 501 
Spatial Span backwards after 2-3 weeks of daily consumption of 12g or more of MCTs. These 502 
findings expand upon previous evidence regarding the positive impact of MCT ingestion on 503 
cognitive performance, specifically within young, healthy individuals. Despite this, the fact 504 
that blood ketones were not measured is a limitation of the study. Furthermore, future research 505 




In conclusion, the present study expanded on previous literature regarding the positive impact 510 
of MCTs on cognitive performance, specifically in young, healthy individuals. Our data 511 
suggests a minimum of 2-3 weeks of MCT gel supplementation is required for participants to 512 
display cognitive improvements, with use of a 30:70 ratio of C8:C10 to eliminate possible 513 
participant withdrawal due to issues of gastrointestinal distress. There also appears to be 514 
minimal differences between 12g and 18g MCT/day for the majority of measures collected. 515 
Therefore, it would be recommended that two MCT gels (2 x 6g) per day are taken to augment 516 
cognitive improvements whilst limiting gastric distress. Future research should establish 517 
whether such improvements are also observed during cognitive demanding tasks, such as those 518 
commonly experienced within sport. 519 
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Table Captions: 526 
Table 1. The ICC’s (%) of each random factor considering the dependent variables. 527 
Table 2. Adjusted means ± SE values for each of the CSoA measures (negative scores indicate 528 
quicker responses to the cued/valid trials than the uncued/invalid). 529 
Table 3. Adjusted mean difference from baseline ± SE values for each of the RVIP measures. 530 
Figure Captions: 531 
Figure 1. Schematic illustrating MCT metabolism in the body. Firstly, MCTs are hydrolysed 532 
in the stomach by pancreatic lipase into medium chain fatty acids (MCFA) which are absorbed 533 
directly into the portal vein [3]. The liver firstly converts MCFA into Acetyl-CoA via β-534 
oxidation. This is then converted into Acetoacetyl-CoA, before becoming β-Hydroxy β-535 
methylglutaryl-CoA (HMG-CoA). This is then metabolised into the ketone Acetoacetate. This 536 
can then further breakdown into βHB and Acetone [1,10]. Acetone is mainly excreted as a 537 
waste product through urine or CO2, but can also enter gluconeogenesis to produce glucose 538 
[10]. Acetoacetate and βHB travel through the blood stream and enter the mitochondria of brain 539 
and muscle cells. Here, more Acetoacetate is generated from βHB via the enzyme 3-β-540 
hydroxybutyrate dehydrogenase (BDH). This is then transformed into Acetoacetyl-CoA via 541 
succinyl-CoA-oxoacid CoA transferase (SCOT). Finally, beta-ketoscyl-CoA metabolises this 542 
into Acetyl-CoA which enters the Krebs Cycle, producing NADH and FADH2 for the Electron 543 
Transport Chain (ETC) [19,20]. The ETC generates 23 molecules of ATP for each Acetoacetate 544 
molecule and 26 molecules of ATP per βHB [58]. 545 
Figure 2. Schematic view of participant flow. 546 
Figure 3. Adjusted mean differences from baseline ± SE values for A) Trail Making A; B) 547 
Trail Making B; C) Digit Span Forwards; D) Digit Span Backwards; E) Spatial Span Forwards; 548 
F) Spatial Span Backwards. * denotes a significant difference between the 12g/18g group and 549 
the Placebo Group; # denotes a significant difference between the 18g group and both the 12g 550 
and Placebo Groups.551 
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Table 1. The ICC’s (%) of each random factor considering the dependent variables. 
 
Dependent Variable ICC (%) 
TM A (score) 46.78* 
TM B (score) 56.45* 
DS Forwards (score) 50.28* 
DS Backwards (score) 49.29* 
SS Forwards (score) 49.87* 
SS Backwards (score) 54.27* 
Exo 100ms mean difference 72.45* 
Exo 800ms mean difference 40.71* 
Endo mean difference 46.46* 
RVIP RT (ms) 68.68* 
RVIP Response to non-target (%) 66.30* 
RVIP Missed Targets (%) 62.49* 
* Represents significant determinant of variance within the linear mixed model (P<0.05). 
ICC = Intraclass Correlation; TM = Trail Making; DS = Digit Span; SS = Spatial Span; Exo 
= Exogenous; Endo = Endogenous; RVIP = Rapid Visual Information Processing; RT = 
Reaction Time. 
  
Table 2. Adjusted mean ± SE values for each of the CSoA measures (negative scores indicate quicker responses to the cued/valid trials than the uncued/invalid). 
  Placebo 12g MCT/day 18g MCT/day 
Week  1 2 3 4 1 2 3 4 1 2 3 4 
 Measure             


















































































Table 3. Adjusted mean difference from baseline ± SE values for each of the RVIP measures. 
  Placebo 12g MCT/day 18g MCT/day 
Week  1 2 3 4 1 2 3 4 1 2 3 4 
 Measure             












































































RVIP = Rapid Visual Information Processing; RT = Reaction Time. * denotes significant effect of time from weeks 1 & 2. 
 
 
 
 
 
 
 
 
 
 
 
